Efficacy and safety of apraglutide in short bowel syndrome with intestinal failure and colon-in-continuity: A multicenter, open-label, metabolic balance study.

Verbiest A, Hvistendahl MK, Bolognani F, Li C, Youssef NN, Huh S, Menys A, Bhatnagar G, Vanslembrouck R, Peeters R, Sartoris R, Vermeersch P and 5 more

Show all authors

Wauters L, Verbeke K, Jeppesen PB, Joly F, Vanuytsel T

Clinical nutrition (Edinburgh, Scotland)16 Oct 2024Cited by 12 (Europe PMC)

PMID39461299DOI10.1016/j.clnu.2024.10.011PepBankPUB-39461299

Publisher page PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanNon-randomized trialSafety outcome
In adults with SBS-IF-CiC receiving apraglutide, 127 adverse events were reported, mostly mild to moderate.
In plain wordsIn adults with short bowel syndrome receiving apraglutide, most reported adverse events were mild to moderate.
Peptide
Apraglutide
Outcome
Not applicableAdverse events
Study
n = 9
Analysis
Primary
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Adverse events reported
127 events
52 weeks
Source sentences
Summary
A total of 127 adverse events was reported, which were mostly mild to moderate.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 52-week phase 2 metabolic balance study (MBS) in 9 adult patients with SBS-IF-CiC receiving once-weekly subcutaneous apraglutide injections.
Report a problemFND-3946129910
02HumanNon-randomized trialEfficacy outcome
In adults with SBS-IF-CiC, apraglutide reduced parenteral support volume by 4702 mL/week (52%) at week 52.
In plain wordsIn adults with short bowel syndrome, intravenous support volume decreased during apraglutide treatment.
Peptide
Apraglutide
Outcome
DecreaseParenteral support volume
Study
n = 9
Analysis
Secondary
Outcome group
Intensive care and hospital outcomes · Gastrointestinal
Studied dose
Dose not stated · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Change in PS volume
−4702 mL/week
week 52
Relative change in PS volume
−52%
week 52
Source sentences
Summary
PS volume decreased by -4702 mL/week (-52 %; p < 0.001) at week 52.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 52-week phase 2 metabolic balance study (MBS) in 9 adult patients with SBS-IF-CiC receiving once-weekly subcutaneous apraglutide injections.
Report a problemFND-3946129901
03HumanNon-randomized trialEfficacy outcome
In adults with SBS-IF-CiC receiving apraglutide, seven patients achieved at least one day off parenteral support at week 52.
In plain wordsIn adults with short bowel syndrome receiving apraglutide, seven patients achieved at least one day without intravenous support.
Peptide
Apraglutide
Outcome
IncreaseAt least one day off parenteral support
Study
n = 9
Analysis
Secondary
Outcome group
Intensive care and hospital outcomes · Gastrointestinal
Studied dose
Dose not stated · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Patients with at least 1 day off PS
7 patients
week 52
Patients with at least 1 day off PS
78%
week 52
Source sentences
Summary
Seven patients (78 %) achieved ≥1 day off PS at week 52.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 52-week phase 2 metabolic balance study (MBS) in 9 adult patients with SBS-IF-CiC receiving once-weekly subcutaneous apraglutide injections.
Report a problemFND-3946129902
04HumanNon-randomized trialEfficacy outcome
In adults with SBS-IF-CiC, fecal output decreased by 253 g/day after apraglutide treatment.
In plain wordsIn adults with short bowel syndrome, stool output decreased during apraglutide treatment.
Peptide
Apraglutide
Outcome
DecreaseFecal output
Study
n = 9
Analysis
Secondary
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
Dose not stated · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Reduction in fecal output
253 g/day
4 weeks
Source sentences
Summary
At 4 weeks, fecal output was reduced by 253 g/day (p = 0.013).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 52-week phase 2 metabolic balance study (MBS) in 9 adult patients with SBS-IF-CiC receiving once-weekly subcutaneous apraglutide injections.
Report a problemFND-3946129903
05HumanNon-randomized trialEfficacy outcome
In adults with SBS-IF-CiC, wet weight absorption increased by 316 g/day during apraglutide treatment.
In plain wordsIn adults with short bowel syndrome, wet weight absorption increased during apraglutide treatment.
Peptide
Apraglutide
Outcome
IncreaseWet weight absorption
Study
n = 9
Analysis
Secondary
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
Dose not stated · subcutaneous · 48 weeksAs given in this study (human).
Measurements
Increase in wet weight absorption
316 g/day
48 weeks
Source sentences
Summary
At 48 weeks, increases in wet weight absorption by 316 g/day (p = 0.039), energy absorption by 1134 kJ/day (p = 0.041) and carbohydrate absorption by 56.1 g/day (p = 0.024) were observed.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 52-week phase 2 metabolic balance study (MBS) in 9 adult patients with SBS-IF-CiC receiving once-weekly subcutaneous apraglutide injections.
Report a problemFND-3946129904
06HumanNon-randomized trialEfficacy outcome
In adults with SBS-IF-CiC, energy absorption increased by 1134 kJ/day during apraglutide treatment.
In plain wordsIn adults with short bowel syndrome, energy absorption increased during apraglutide treatment.
Peptide
Apraglutide
Outcome
IncreaseEnergy absorption
Study
n = 9
Analysis
Secondary
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
Dose not stated · subcutaneous · 48 weeksAs given in this study (human).
Measurements
Increase in energy absorption
1134 kJ/day
48 weeks
Source sentences
Summary
At 48 weeks, increases in wet weight absorption by 316 g/day (p = 0.039), energy absorption by 1134 kJ/day (p = 0.041) and carbohydrate absorption by 56.1 g/day (p = 0.024) were observed.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 52-week phase 2 metabolic balance study (MBS) in 9 adult patients with SBS-IF-CiC receiving once-weekly subcutaneous apraglutide injections.
Report a problemFND-3946129905
07HumanNon-randomized trialEfficacy outcome
In adults with SBS-IF-CiC, carbohydrate absorption increased by 56.1 g/day during apraglutide treatment.
In plain wordsIn adults with short bowel syndrome, carbohydrate absorption increased during apraglutide treatment.
Peptide
Apraglutide
Outcome
IncreaseCarbohydrate absorption
Study
n = 9
Analysis
Secondary
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
Dose not stated · subcutaneous · 48 weeksAs given in this study (human).
Measurements
Increase in carbohydrate absorption
56.1 g/day
48 weeks
Source sentences
Summary
At 48 weeks, increases in wet weight absorption by 316 g/day (p = 0.039), energy absorption by 1134 kJ/day (p = 0.041) and carbohydrate absorption by 56.1 g/day (p = 0.024) were observed.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 52-week phase 2 metabolic balance study (MBS) in 9 adult patients with SBS-IF-CiC receiving once-weekly subcutaneous apraglutide injections.
Report a problemFND-3946129906
08HumanNon-randomized trialEfficacy outcome
In adults with SBS-IF-CiC receiving apraglutide, small bowel length increased from 29.7 to 40.7 cm.
In plain wordsIn adults with short bowel syndrome receiving apraglutide, small bowel length increased.
Peptide
Apraglutide
Outcome
IncreaseSmall bowel length
Study
n = 9
Analysis
Secondary
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Small bowel length
29.7 cm
before
Small bowel length
40.7 cm
after
Source sentences
Summary
Moreover, small bowel length increased from 29.7 to 40.7 cm (p = 0.012), duodenal wall thickness increased by 0.8 mm (p = 0.02) and motility in the proximal colon was reduced (p = 0.031).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 52-week phase 2 metabolic balance study (MBS) in 9 adult patients with SBS-IF-CiC receiving once-weekly subcutaneous apraglutide injections.
Report a problemFND-3946129907
09HumanNon-randomized trialEfficacy outcome
In adults with SBS-IF-CiC receiving apraglutide, duodenal wall thickness increased by 0.8 mm.
In plain wordsIn adults with short bowel syndrome receiving apraglutide, the duodenal wall became thicker.
Peptide
Apraglutide
Outcome
IncreaseDuodenal wall thickness
Study
n = 9
Analysis
Secondary
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Increase in duodenal wall thickness
0.8 mm
apraglutide
Source sentences
Summary
Moreover, small bowel length increased from 29.7 to 40.7 cm (p = 0.012), duodenal wall thickness increased by 0.8 mm (p = 0.02) and motility in the proximal colon was reduced (p = 0.031).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 52-week phase 2 metabolic balance study (MBS) in 9 adult patients with SBS-IF-CiC receiving once-weekly subcutaneous apraglutide injections.
Report a problemFND-3946129908
10HumanNon-randomized trialEfficacy outcome
In adults with SBS-IF-CiC receiving apraglutide, proximal colon motility decreased.
In plain wordsIn adults with short bowel syndrome receiving apraglutide, movement in the proximal colon decreased.
Peptide
Apraglutide
Outcome
DecreaseProximal colon motility
Study
n = 9
Analysis
Secondary
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Moreover, small bowel length increased from 29.7 to 40.7 cm (p = 0.012), duodenal wall thickness increased by 0.8 mm (p = 0.02) and motility in the proximal colon was reduced (p = 0.031).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 52-week phase 2 metabolic balance study (MBS) in 9 adult patients with SBS-IF-CiC receiving once-weekly subcutaneous apraglutide injections.
Report a problemFND-3946129909

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Efficacy and safety of apraglutide in short bowel syndrome with intestinal failure and colon-in-continuity: A multicenter, open-label, metabolic balance study.

Summary

Results from this study10

Version history

Subjects

Publication types

MeSH terms

Keywords